Aminex Therapeutics, Inc., is a drug development  company focused on  discovery, development, and commercialization of a new subclass of cancer immunotherapies known as suppressor cell modulators (SCMs). Aminex’s novel cancer immunotherapy drug, AMX-513, enables the body’s immune system to attack cancer and its ability to spread by modulating myeloid-derived suppressor cells (MDSCs).

Aminex has operated primarily with angel funding since its founding in 2009. The company recently completed a very successful Series A financing round, raising more than $4 million, which is programmed to complete remaining FDA preclinical requirements and preparation for AMX-513 human clinical trials scheduled to start in mid-2016.

An extensive array of animal data supports the likelihood that AMX-513 will be effective in human cancer clinical trials. Our vision is for AMX-513 to be a transformational drug therapy, for use alone or in combination with other immunotherapy treatments.

Though there have been important incremental improvements in cancer treatment, the incidence of cancer is rising in the United States and throughout the world. Furthermore, cancer survival longevity is unacceptably low, and treatment costs have been growing rapidly. Aminex’s goal is to substantially improve these trends.